# Study to Assess the Efficacy, Safety, and Tolerability of Valbenazine for the Treatment of Dyskinesia Due to Cerebral Palsy

> **NCT05206513** · PHASE3 · COMPLETED · sponsor: **Neurocrine Biosciences** · enrollment: 86 (actual)

## Conditions studied

- Dyskinesia
- Cerebral Palsy

## Interventions

- **DRUG:** Placebo
- **DRUG:** Valbenazine

## Key facts

- **NCT ID:** NCT05206513
- **Lead sponsor:** Neurocrine Biosciences
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2022-04-15
- **Primary completion:** 2025-10-16
- **Final completion:** 2026-03-31
- **Target enrollment:** 86 (ACTUAL)
- **Last updated:** 2026-04-29


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05206513

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05206513, "Study to Assess the Efficacy, Safety, and Tolerability of Valbenazine for the Treatment of Dyskinesia Due to Cerebral Palsy". Retrieved via AI Analytics 2026-06-23 from https://api.ai-analytics.org/clinical/NCT05206513. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*